Allergology International

This is a promotion site for the
Allergology International. You can see
the journal contents in Science Direct

Current Issue |
Volume 71, Issue 2
April 2022

Cover of Allergology International

Open Access ISSN: 1323-8930
2020 Impact Factor: 5.836
View More on Journal Insights
© 2021 Journal Citation Reports
© Clarivate Analytics, 2021

Appreciation to Reviewers

The Editors are deeply appreciative of their valuable expertise and contributions to AI. See more

Outstanding Reviewers 2021

About Allergology International

Allergology International is the official journal of the Japanese Society of Allergology and publishes original papers dealing with the etiology, diagnosis and treatment of allergic and related diseases. Papers may include the study of methods of controlling allergic reactions, human and animal models of hypersensitivity and other aspects of basic and applied clinical allergy in its broadest sense.

The Journal aims to encourage the international exchange of results and encourages authors from all countries to submit papers in the following three categories: Original Articles, Review Articles, and Letters to the Editor.

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.

Editor's Choices

Original Article

Editor’s comment: MUC5AC and MUC5B are the major secreted polymeric mucins in airways, but in asthmatic patients, their pathophysiological relevance remains unclear. In this cross-sectional study of patients with steroid-untreated mild asthma and healthy controls, Tajiri et al. showed that sputum MUC5AC and MUC5B levels were significantly higher in patients with asthma than in controls. In addition, they showed that sputum MUC5AC levels positively correlated with FeNO, sputum eosinophil proportion, and airway sensitivity, suggesting the involvement of MUC5AC in type 2/eosinophilic airway inflammation.

Original Article

Editor’s comment: Although oral food challenge tests (OFCs) are the gold standard for food allergy diagnosis, little is known about the optimal interval between antigen ingestion. In this study, Kitamura et al. evaluated the total symptom score, total ingested dose, and the proportions of severe reactions and adrenaline use. They did a retrospective chart review of 945 OFCs, eliciting objective reactions to wheat, egg, and milk. They showed that a 60-minute interval is safer than a 30- or 40-minute interval for OFCs in patients with a low threshold dose for food allergy.

Original Article

Editor’s comment: Serological testing is important in diagnosing food allergy to avoid risks such as anaphylaxis from oral food challenge tests. With respect to tree nuts, singleplex tests for allergen components showed diagnostic utility for cashew/pistachio, hazelnut, and walnut allergies. In this study, Akarsu et al. investigated the utility of multiplex tests (i.e., ALEX2) in diagnosing tree nut allergy in 169 children. They showed that a multiplex component-based allergen macroarray test is as reliable and useful as a singleplex assay for predicting tree nut-allergies in children.

Review Series: Linking Drug-Allergy and Autoimmune Diseases

Invited Review Article

Hamaguchi provides a comprehensive review of drug-induced scleroderma-like lesions, including frequency, causative drugs, mechanisms, clinical features and comparison with systemic sclerosis (SSc). A wide variety of drugs can cause scleroderma-like lesions, including chemotherapeutics. Unlike SSc, most cases are negative for autoantibodies, have no vascular abnormalities, and seem to have minimal organ damage. In recent years, however, there has been an increasing number of reports of scleroderma-like lesions due to immune checkpoint inhibitor (ICI), including cases in which patients with pre-existing SSc had their organ involvement worsened by induction of ICI.

Invited Review Article

Okiyama and Tanaka offer an excellent review of ICI-induced irAE, including its epidemiology, risk factors, clinical phenotypes of cutaneous irAE, and management. While the activation of CD8+ T cells by ICI is important for the original purpose of cancer immunity, CD8+ T as well as B cells are also involved in irAE. In addition, cytokines and microbiomes associated with the development of irAEs have also been reported. Further studies may identify risk factors, biomarkers, and appropriate treatments as well as prevention of irAEs without loss of cancer immunity by ICI.

Invited Review Article

Watanabe and Yamaguchi's review article focuses on the association between drug allergy and autoimmune diseases. The high frequency of drug eruptions in patients with SS, SLE, and adult-onset Still's disease is comprehensively reviewed. Intriguing observations include the development of SS-like symptoms after SJS/TEN onset and the high prevalence of anti–SS–A antibodies in SJS/TEN. SLE is a known risk factor for SJS/TEN, but both may involve common pathologies such as excessive immune responses, dysregulated regulatory T cell function, and neutrophil extracellular traps.

Invited Review Article

Sueki et al. give us an intriguing review focusing on the relationship between the immune mechanism of non-HIV IRIS and drug allergies. The pathophysiology of non-HIV IRIS can be recognized in several disorders treated with corticosteroids, immunosuppressants, molecular-targeted drugs, TNF-α antibody drugs, immune checkpoint inhibitors, and dipeptidyl peptidase-4 inhibitors. They describe the concept and draft the diagnostic criteria of non-HIV IRIS, comprehensively reviewing DIHS/DRESS, SJS/TEN, DPP4 inhibitor-related bullous pemphigoid, and irAE as events associated with non-HIV IRIS. This interesting field awaits the development of biomarkers that can help diagnose and predict the development of IRIS.

To Top